According to a new report Asia Pacific Cardiac Biomarkers Testing Market, published by KBV research, the Asia Pacific Cardiac Biomarkers Testing Market would witness market growth of 12.1% CAGR during the forecast period (2019-2025).
The China market dominated the Asia Pacific Acute Coronary Syndrome Market by Country in 2018, growing at a CAGR of 13.2 % during the forecast period. The Japan market is expected to witness a CAGR of 9.9% during (2019 - 2025). Additionally, The India market is expected to witness a CAGR of 13.2% during (2019 - 2025).
The Laboratory Testing market dominated the Asia Pacific Cardiac Biomarkers Testing Market by Location of Testing in 2018, growing at a CAGR of 11.6 % during the forecast period. The Point of Care Testing market is expected to witness highest CAGR of 15% during (2019 - 2025).
The Troponins market dominated the Malaysia Cardiac Biomarkers Testing Market by Type in 2018, thereby, achieving a market value of $45.3 million by 2025, growing at a CAGR of 13.6 % during the forecast period. The Ischemia Modified Albumin market is expected to witness a CAGR of 16.9% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/asia-pacific-cardiac-biomarkers-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Trivitron Healthcare Pvt. Ltd., ABBOTT Laboratories, Siemens AG, Becton, Dickinson AND Company, Bio-Rad laboratories, Inc., Randox Laboratories Limited, Danaher Corporation, Thermo Fisher Scientific, Inc., Johnson and Johnson and Quidel Corporation.
By Type
By Application
By Location of Testing
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
